TVTX Biotech · Rare disease · Kidney disease · Commercial biotech · Thesis updated July 12, 2026

FILSPARI now has to carry Travere

FILSPARI is now approved for IgAN and FSGS, giving Travere one main drug with two rare kidney disease markets.
Management now sees more than 100,000 eligible U.S. patients and a $3 billion peak sales chance for FILSPARI.
Q1 2026 FILSPARI net sales were $105.2 million, up from $55.9 million in Q1 2025 before the FSGS approval.
The Thiola line still brings in money, but generic competition is a direct threat to that older cash source.
Pegtibatinase is back in Phase 3 enrollment, but its key data is not expected until the second half of 2027.

01 Running thesis

One drug, bigger target

Travere is now a FILSPARI execution story. The drug already sells for IgA nephropathy, or IgAN, a kidney disease that can lead to kidney failure. In April 2026, the FDA also approved FILSPARI for focal segmental glomerulosclerosis, or FSGS, in patients without nephrotic syndrome. That turns one product into a two-market launch.

The bull case is simple. Management says more than 100,000 U.S. patients could be eligible across IgAN and FSGS, and it now sees a $3 billion peak sales chance for FILSPARI. Q1 2026 demand looked strong, with 993 new patient start forms and $105.2 million of FILSPARI net sales. Early FSGS launch comments also sound positive, with management pointing to fast patient starts and good payer approval rates.

The bear case is also clear. Travere has set a high bar by saying FSGS should ramp faster than IgAN. If doctors are confused by the FSGS label, if the real patient pool is smaller, or if IgAN growth slows because of competition, the stock could lose a key part of its growth story.

The next test is transparency. Management said it will not break out patient start forms by indication. That makes it harder for investors to tell whether IgAN is still growing, whether FSGS is really taking off, or whether the combined number is hiding weakness in one bucket.

May 2026▲Management introduced a $3 billion peak sales estimate for FILSPARI across IgAN and FSGS, supported by more than 100,000 eligible U.S. patients. The same call raised the tracking risk because the company will not split patient start forms by indication.

May 2026▲The Q1 2026 filing confirmed full FDA approval of FILSPARI for FSGS on April 13, 2026. It also showed FILSPARI net sales of $105.2 million and set pegtibatinase topline data timing for the second half of 2027.

Feb 2026▲The FY2025 filing showed FILSPARI net sales of $322.0 million for 2025 and confirmed the HARMONY study restart plan. The FSGS review date moved to April 13, 2026, delaying but not ending the catalyst.

Oct 2025▲The FDA said an advisory committee was no longer needed for the FSGS application. That removed a major overhang while Q3 FILSPARI sales of $90.9 million showed continued commercial strength.

Aug 2025▲The FDA accepted the FSGS application and set a January 13, 2026 target action date. Q2 FILSPARI sales of $71.9 million strengthened the launch case.

May 2025▲Travere submitted the FSGS application, turning a possible expansion into a clear regulatory event. Q1 2025 FILSPARI sales reached $55.9 million, while Thiola revenue held at $20.0 million despite generic pressure.

Feb 2025→Travere said it planned to submit a FILSPARI FSGS application by the end of Q1 2025, reviving a key upside case. At the same time, multiple Thiola EC generics made the older product line risk more real.

Oct 2024→FILSPARI received full FDA approval in IgAN, which lowered risk around the core product. That gain was balanced by a voluntary HARMONY enrollment pause tied to pegtibatinase manufacturing scale-up.

02 Business model

Selling rare disease drugs

Travere makes money mostly by selling approved drugs in the U.S. Its main product is FILSPARI. It also sells Thiola and Thiola EC for cystinuria, a rare disorder that causes kidney stones.

Outside the U.S., Travere does not do every launch itself. It licenses sparsentan rights to CSL Vifor for Europe, Australia, and New Zealand, and to Chugai for Japan, South Korea, and Taiwan. Those deals can bring in milestones and royalties, which are high-value revenue if partner sales grow.

The model works best when a rare disease drug has strong patent protection, clear payer coverage, and doctors who know which patients should get it. It breaks if launch uptake is slower than expected, if insurers push back, or if generic competition eats older products faster than FILSPARI can grow.

03 Product portfolio

What Travere sells and studies

Growth engine

FILSPARI for IgAN

FILSPARI is approved to slow kidney function decline in adults with IgAN at risk of progression. It is the base of Travere's current growth, with Q1 2026 net sales of $105.2 million across FILSPARI before much FSGS contribution.

Growth engine

FILSPARI for FSGS

The FDA granted full approval on April 13, 2026, for certain FSGS patients aged 8 years and older. Management expects uptake to be faster than the IgAN launch, which creates both upside and execution risk.

Cash cow

Thiola and Thiola EC

These tiopronin products treat cystinuria. They produced $19.3 million of Q1 2026 net product revenue, but several approved generics make this a shrinking profit support over time.

Option

Pegtibatinase

Pegtibatinase is in the Phase 3 HARMONY study for classical homocystinuria, a rare metabolic disease. Enrollment restarted in Q1 2026, the first new patient was dosed in April 2026, and topline data is expected in the second half of 2027.

Option

PharmaKrysto cystinuria collaboration

Travere also has an early-stage cystinuria program with PharmaKrysto. It is too early to carry the company, but it fits the rare kidney disease focus.

04 Business segments

Q1 revenue mix

FILSPARI83%growing fast

Tiopronin products15%declining

License and collaboration revenue2%flat

Travere reports as one operating segment, so this mix uses Q1 2026 revenue by product and type. FILSPARI was about 83% of Q1 2026 revenue, which shows how concentrated the story has become.

05 Risk factors

What could break the story

FSGS launch misses the fast-ramp claim

High impact · Medium odds

Management has said FSGS uptake should be faster than the IgAN launch. That may not happen if doctors pause over the label language, especially the limit to patients without nephrotic syndrome, or if the real treated population is smaller than expected.

We watchQ2 and Q3 2026 FILSPARI sales growth, payer approval comments, and any launch comments on FSGS patient starts.

IgAN growth slows under competition

High impact · Medium odds

FILSPARI already had strong IgAN demand, including 993 new patient start forms in Q1 2026. But IgAN is an active market with other approved options, and a slowdown would make the $3 billion peak sales goal harder to believe.

We watchTotal FILSPARI patient start forms, repeat prescribing, and quarterly sales growth after the company stops splitting PSFs by indication.

Thiola fades faster than planned

Medium impact · High odds

Thiola and Thiola EC still matter because they help fund the company. Several generic versions are approved, so sales could erode faster and leave a gap before FILSPARI or royalties fully offset it.

We watchQuarterly tiopronin product revenue, especially drops from the Q1 2026 level of $19.3 million.

Pegtibatinase stumbles again

Medium impact · Medium odds

The HARMONY study has restarted, but it had been paused because of manufacturing scale-up issues. If those problems return, or if Phase 3 data fails in the second half of 2027, Travere loses its main pipeline option.

We watchHARMONY enrollment updates, manufacturing comments, and any change to the second half of 2027 topline data timeline.

Profitability stays out of reach

High impact · Medium odds

Travere has a history of operating losses. The path to sustained profit depends on FILSPARI growing fast enough across two uses while the company keeps funding clinical work and absorbs Thiola pressure.

We watchOperating loss trend, cash use, FILSPARI revenue growth, and spending tied to the FSGS launch and HARMONY study.

06 Quick answers

In one breath

What does Travere Therapeutics do?

Travere develops and sells drugs for rare kidney and metabolic diseases. Its main product is FILSPARI, which is approved for IgAN and certain FSGS patients.

Why does FILSPARI matter so much to TVTX stock?

FILSPARI is the main growth engine. Management now sees a $3 billion peak sales chance across IgAN and FSGS, so the stock depends heavily on whether that launch keeps growing.

What is the biggest near-term catalyst for Travere?

The next big readouts are not clinical data, but launch data. Q2 and Q3 2026 results should give the first real numbers on whether FSGS is adding meaningful growth.

What is pegtibatinase?

Pegtibatinase is Travere's Phase 3 drug candidate for classical homocystinuria. The HARMONY study restarted enrollment in Q1 2026, with topline data expected in the second half of 2027.